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Immunological tolerance to thymus-independent  (TI) antigens can be readily 
induced by the injection of supraimmunogenic doses of the antigens.  Although 
tolerance to certain  TI antigens,  such  as lipopolysaccharide  (LPS)  can be re- 
versed by transferring tolerant cells to irradiated animals or by simply incubat- 
ing the cells in  culture  in the  absence of antigen  (1),  other TI antigens  like 
dextrans and levans induce a stable nonreversible state of specific tolerance (2). 
Tolerance to TI antigens like dextran represents a direct effect on the antigen- 
specific B cells and the participation of suppressor cells has been excluded (3). It 
has been suggested that B lymphocytes are tolerized when the Ig receptors bind 
the antigen  (signal  1) in the absence of a  second signal (4).  Here we will show 
that  specific  immunological  tolerance  only  affects  a  particular  subset  of B 
lymphocytes, whereas other B cells having the same immunological specificity 
are neither activated nor tolerized by interacting with the antigen. The variable 
that determines whether B cells become tolerant to a  particular  TI antigen is 
their susceptibility to the polyclonal B-cell-activating property of the antigen. 
Results 
The  TI  antigen  used  was  fluorescein  isothiocyanate-dextran  B512  (FITC- 
dextran),  which  was  manufactured  by Pharmacia  Fine  Chemicals,  Uppsala, 
Sweden. Three preparations with different mol wt (150,000,  500,000,  and l0  T  the 
latter  being native  dextran)  were tested.  They all  contained  1 FITC  per  200 
glucose residues. Mice were rendered tolerant to FITC-dextran by the intraperi- 
toneal injection of 10 mg (with native FITC-dextran)  or 100 mg of the antigen 
(with the  other preparations).  At  4-  to  10 days after tolerance  induction  the 
spleens were removed and the number of anti-FITC plaque-forming cells (PFC) 
was determined by the Jerne and Nordin plaque assay (5).  Untreated mice or 
mice immunized with 100/~g of FITC-dextran served as controls. As can be seen 
in  Fig.  1,  (an  experiment  with  native  FITC-dextran)  tolerance  induction  re- 
sulted in a  complete loss of anti-FITC  PFC.  The spleen cells from these mice 
were  cultivated  in  vitro  with  no  additions  for  24  h  in  serum-free  cultures, 
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Fro.  1.  Anti-FITC PFC in untreated (C3H  x  DBA)F1 mice or mice injected 6 days before 
with an immunogenic (100  ~g) or telerogenic (10 mg) dose  of FITC-native dextran.  The 
response (three mice/group) was tested on FITC coated sheep erythrocytes by using a very 
low concentration of FITC (0.05 mg/ml) to detect cells with high affinity for the antigen, as 
described  before  (6). 
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FIG.  2.  Cells from the animals in Fig. 1 were cultivated for 24 h in serum-free medium, 
harvested, and recultivated in 5% human A serum by using 3 x  105 cells/ml in 2 ml in 35- 
mm diameter Petri dishes in the presence of the indicated polyclonal B-cell activators. The 
following PBA  concentrations were  used:  LPS  100  pg/ml,  PPD  100  ~g/ml,  and native 
dextran (Dex)  10 mg/ml. The cells were harvested on day 3 and tested against FITC  as 
described in Fig. 1. Bg indicates the response in nonstimulated cultures. 
harvested, and recultured in the presence of various polyclonal B-cell activators, 
such as  LPS,  purified protein derivative of tuberculin  (PPD),  and native  dex- 
tran.  The  high  affinity  anti-FITC  response  was  determined  after  2  days  (by 
using l0  T cells/ml) or 3-7 days (by using 3  ×  105 cells/ml). The results were the 
same  in all  culture  systems  employed  and  with all  MW  preparations  used  as 
shown in Figs.  2 and 3. It was consistently found that activation by LPS caused 310  C.  FERNANDEZ  AND  G.  MOLLER  BRIEF  DEFINITIVE  REPORT 
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FIG. 3.  Cells  from 4 R animals tolerized  5 days earlier  by an injection  of  i00 mg FITC- 
dextran (Dex) 150 were cultivated  for  24 h in  serum-free medium, harvested,  washed, and 
recultivated  in  serum-free medium by  using  107  cells/ml  in  35-mm plastic  Petri  dishes  in  the 
presence of  100 ~g/ml of  LPS, 10 mg/ml of  native dextran or 100/~g/ml of  PPD. The cells 
were  harvested 2  days  later  and  assayed  for  high  affinity  anti-FITC  PFC as  described  in  Fig. 
1. 
the appearance of high affinity PFC against FITC to the same extent with cells 
from untreated and tolerant mice. PPD was usually less efficient with cells from 
tolerant animals.  In contrast,  activation of the cells by polyclonally-activating 
concentrations of native dextran caused the appearance of anti-FITC PFC only 
in cultures with cells from untreated  and immunized  mice, but not with cells 
from tolerant animals. 
Discussion 
These findings show that cells from animals rendered completely tolerant to 
the FITC-dextran  conjugate can be activated by LPS and often by PPD to the 
synthesis of high affinity PFC against the hapten FITC to the same extent as 
cells from untreated animals.  It follows that the anti-FITC reactive cells in the 
subsets of B  cells that can be activated by LPS and  PPD had not been made 
unresponsive  to  FITC.  In  contrast,  polyclonally-activating  concentrations  of 
native dextran failed to activate cells from tolerant animals to the synthesis of 
anti-FITC  PFC.  Obviously,  only some B  cells capable of reacting  with  FITC 
were made tolerant  of FITC,  namely those  B  cells that  could respond  to the 
polyclonal B-cell activating properties of the dextran carrier.  Since B  cells in 
different  subsets  have  the  same  repertoire  of V  genes  (7),  the  interaction 
between the antigen and the antigen-binding Ig receptors cannot by itself cause 
a  tolerance signal.  Since only the B cells that could respond to the polyclonal- 
activating  property  of the  antigen  were  made  tolerant,  it  follows  that  the 
polyclonal  B-cell-activating  (PBA)  property  of the  antigen  is  responsible  for 
tolerance induction. 
These findings have far reaching implications for our understanding of signal 
delivery in lymphocyte activation and tolerance.  They are clearly incompatible 
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Fie.  4.  Schematic summary of the  results.  FITC-dextran is illustrated  as a  molecule 
having two different determinants: the FITC epitope (open squares) and the PBA determi- 
nant (black circle).  When FITC-dextran binds to the Ig receptor of anti-FITC reactive B 
cells, only those cells having PBA receptors for dextran will be activated (upper cell to the 
left), whereas other antigen-specific  cells having different PBA receptors are not activated 
(upper cell to the right). When tolerogenic doses of the antigen is given, the cells with PBA 
receptors for dextran become tolerized (lower cell to the left), whereas other anti-FITC cells 
having different PBA receptors are not tolerized (lower cell to the right).  These cells can be 
activated by a pelyclonal B-cell activator that can interact with the particular PBA receptor 
of that subpopulation,  as indicated  in the figure by a molecule having a different antigenic 
determinant (open D) and a different  PBA determinant (black square). 
the  antigen to the Ig receptors,  results  in tolerance  induction,  whereas signal 
one plus a  second signal which can be delivered by e.g. collaborating T  cells or 
by PBA properties of TI antigen, cause lymphocyte activation. Our experiments 
show that signal one by itself neither can activate nor tolerize antigen-specific B 
cells  (Fig.  4).  Both  activation  and  induction  of specific  tolerance  necessarily 
required that the B cells possessed receptors for the polyclonal B-cell-activating 
properties of the TI antigen used as carrier. These findings are only compatible 
with  the  one  nonspecific  signal  hypothesis  of lymphocyte  activation,  which 
states that the activating signal is delivered only by polyclonal B-cell-activating 
properties of the TI antigen and that the Ig receptors do not signal any event in 
the B  cells, but serve as passive focussing devices that allow the antigen to be 
focussed  selectively  to  the  antigen-specific  cells.  The  selective  induction  of 
tolerance  in  those  B  cells  that  respond  to  the  polyclonal  B-cell  activating 
properties of the antigen cannot be accommodated by any theory of lymphocyte 
activation  that  ascribes  a  signalling  event  by  the  interaction  between  the 
antigen and the Ig receptors. 312  c.  FERNANDEZ  AND  G.  MOLLER  BRIEF  DEFINITIVE  REPORT 
Summary 
Mice were rendered specifically tolerant to the fluorescein isothiocyanate- 
dextran (FITC) epitope by injection of FITC-dextran B512.  Their spleen cells 
were removed at various times and cultivated in vitro with different polyclonal 
B-cell activators, such as lipopolysaccharide (LPS), purified protein derivative 
of tuberculin, and native dextran. LPS caused the appearance of high affinity 
anti-FITC plaque-forming cells to an equal extent with cells from untreated and 
tolerant animals, whereas native dextran failed to activate cells from tolerant 
mice, although it was a potent activator of normal cells. It was concluded that 
tolerance induction only affects those B cells that could respond to the polyclonal 
B-cell-activating properties of the tolerogen, but not other B  cells having an 
identical set of Ig receptors directed against the tolerogen. 
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